MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Anti-Ovarian Cancer Compound Library

MCE 站：Anti-Ovarian Cancer Compound Library

Ovarian Cancer is the most common cause of death in female genital malignancies, with the highest mortality rate in female genital malignancies. It is characterized by difficulty in detection in the early stage of the disease, high recurrence rate ａnd poor prognosis. In fact, ovarian cancer includes many pathologic types. It is usually divided into epithelial ovarian cancer, malignant germ cell tumors ａnd sex cord stromal tumors, of which epithelial ovarian cancer is the most dominant form. Clinical treatment of ovarian cancer prioritizes surgery combined with paclitaxel chemotherapy. However, due to the spread ａnd drug resistance of tumor cells, the recurrence of ovarian cancer is high. In this case, combined with traditional methods, the development of new therapeutic agents can help to improve the treatment effect of ovarian cancer.MCE designs a unique collection of 1711 compounds with definite or potential anti-ovarian cancer activity, which mainly targeting the main targets of ovarian cancer such as PARP, ATM/ATR, VEGFR ａnd HIF/HIF Prolyl-Hydroxylase, etc. It is an essential tool for development ａnd research of anti-ovarian compounds.

Description & Advantages:

   A unique collection of 1711 with identified ａnd potential anti-ovarian cancer activity for high throughput screening (HTS) ａnd high content screening (HCS).

   The library contains compounds targeting the PARP, ATM/ATR, VEGFR, HIF/HIF Prolyl-Hydroxylase, etc.

   A useful tool for the discovery of anti-ovarian cancer compounds.

   Bioactivity ａnd safety confirmed by preclinical research ａnd clinical trials. Some compounds have been approved by FDA.

   Structurally diverse, bioactive, ａnd cell permeable.

   More detailed compound information with structure, IC50, ａnd other chemical & biological data.

   High purity ａnd quality validated by NMR ａnd LC/MS.

   All compounds are in stock ａnd continuously updated.

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。